Trials / Completed
CompletedNCT00430534
Evaluation of Safety, Immune-Response and Efficacy of GSK Biologicals' EBV (Epstein Barr Virus) Vaccine (268664).
To Evaluate the Safety, Immunogenicity and Efficacy of GSK Biologicals' EBV Vaccine (268664) in Healthy Seronegative Adolescents/Adults When Injected Intramuscularly According to a 0-1-5 Month Schedule in Belgium.
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 200 (planned)
- Sponsor
- Henogen · Industry
- Sex
- All
- Age
- 16 Years – 25 Years
- Healthy volunteers
- Accepted
Summary
To evaluate the safety, immune-response and efficacy of GSK Biologicals' EBV vaccine in a population at risk of developing infectious mononucleosis. Each subject will receive three doses of vaccine or placebo during the study period.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | EBV vaccine (268664) |
Timeline
- First posted
- 2007-02-02
- Last updated
- 2007-02-02
Locations
1 site across 1 country: Belgium
Source: ClinicalTrials.gov record NCT00430534. Inclusion in this directory is not an endorsement.